.svg){kind=small}
Jan-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In examining Avexia's performance across different categories and states, there are notable consistencies and shifts. In Illinois, Avexia has maintained a strong position in the Capsules category, consistently ranking 2nd from October 2025 to January 2026. However, the brand's performance in the Concentrates category in Illinois shows a downward trend, with rankings slipping from 23rd in October 2025 to 28th by January 2026. This decline could suggest a growing competition or a shift in consumer preferences within the state. In the Topical category, Avexia has held the top spot throughout the same period, indicating a robust market presence and consumer loyalty in Illinois.
In New Jersey, Avexia has shown a dynamic performance, especially in the Tincture & Sublingual category where they emerged in 4th place by January 2026 after not being in the top 30 previously. This indicates a significant breakthrough in this category. Meanwhile, their standing in the Concentrates category has fluctuated, yet they remained within the top 15, suggesting a stable yet competitive position. In Maryland, Avexia's Capsules category saw a slight dip from 2nd to 3rd place by January 2026, while their Topical products rose to the top rank by December 2025, maintaining it into the new year. These movements highlight Avexia's varying strengths and challenges across different markets and product categories.
Competitive Landscape
In the Illinois topical cannabis market, Avexia has consistently maintained its top position from October 2025 through January 2026, demonstrating a strong brand presence and consumer preference. This stability in rank is particularly notable given the competitive landscape, where Doctor Solomon's has consistently held the second position, albeit with significantly lower sales figures. Avexia's sales have shown a fluctuating trend, peaking in December 2025 before experiencing a dip in January 2026. Meanwhile, Pheotera Grove has remained in the fourth position, with sales figures that are considerably lower than both Avexia and Doctor Solomon's. This consistent ranking and sales performance suggest that Avexia's market strategy and product offerings are effectively resonating with consumers, allowing it to maintain a leading edge over its competitors.
Notable Products
In January 2026, the top-performing product from Avexia was the CBD/THC 1:1 Harmony Pain Relief Balm in the Topical category, maintaining its consistent number one rank from previous months despite a slight dip in sales to 6,682 units. The CBN/CBD/THC 1:1:1 Comfort Tablets in the Capsules category held their position at rank two, showcasing a steady increase in sales over the months. The CBD/THC 4:1 Relief Tablets climbed back to the third position after dropping to fifth in December, indicating a resurgence in consumer preference. The CBG/THC 1:1 Ascend Tablets remained stable at fourth place, while the CBD/THC 1:1 Harmony Micro-Dosed Tablets slipped to fifth, reflecting a slight decrease in demand. Overall, the product rankings show minor fluctuations, with the top two positions remaining unchanged since October 2025.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
